THAR vs. CANF, EDSA, GLTO, UNCY, TLPH, BCTX, FLGC, KTRA, UPC, and AVTX
Should you be buying Tharimmune stock or one of its competitors? The main competitors of Tharimmune include Can-Fite BioPharma (CANF), Edesa Biotech (EDSA), Galecto (GLTO), Unicycive Therapeutics (UNCY), Talphera (TLPH), BriaCell Therapeutics (BCTX), Flora Growth (FLGC), Kintara Therapeutics (KTRA), Universe Pharmaceuticals (UPC), and Avalo Therapeutics (AVTX). These companies are all part of the "pharmaceutical preparations" industry.
Can-Fite BioPharma (NYSE:CANF) and Tharimmune (NASDAQ:THAR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability, valuation and community ranking.
Can-Fite BioPharma has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Tharimmune has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500.
Can-Fite BioPharma received 3 more outperform votes than Tharimmune when rated by MarketBeat users.
21.0% of Can-Fite BioPharma shares are owned by institutional investors. Comparatively, 1.2% of Tharimmune shares are owned by institutional investors. 0.8% of Can-Fite BioPharma shares are owned by company insiders. Comparatively, 2.4% of Tharimmune shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Tharimmune has a net margin of 0.00% compared to Tharimmune's net margin of -1,027.46%. Tharimmune's return on equity of -113.75% beat Can-Fite BioPharma's return on equity.
Can-Fite BioPharma currently has a consensus price target of $18.00, suggesting a potential upside of 407.04%. Given Tharimmune's higher probable upside, analysts plainly believe Can-Fite BioPharma is more favorable than Tharimmune.
In the previous week, Tharimmune had 1 more articles in the media than Can-Fite BioPharma. MarketBeat recorded 2 mentions for Tharimmune and 1 mentions for Can-Fite BioPharma. Can-Fite BioPharma's average media sentiment score of 0.96 beat Tharimmune's score of 0.88 indicating that Tharimmune is being referred to more favorably in the news media.
Can-Fite BioPharma has higher revenue and earnings than Tharimmune.
Summary
Can-Fite BioPharma beats Tharimmune on 9 of the 14 factors compared between the two stocks.
Get Tharimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for THAR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding THAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Tharimmune Competitors List
Related Companies and Tools
Free THAR Stock Alerts